BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Price Down 3.4% – Time to Sell?

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) shares dropped 3.4% on Tuesday . The stock traded as low as $7.65 and last traded at $7.66. Approximately 84,786 shares were traded during mid-day trading, a decline of 96% from the average daily volume of 2,174,724 shares. The stock had previously closed at $7.93.

Analyst Ratings Changes

A number of equities research analysts have recently commented on the company. Evercore ISI lifted their price objective on BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the company an “outperform” rating in a research report on Monday. Royal Bank of Canada reaffirmed an “outperform” rating and set a $10.00 price target on shares of BioCryst Pharmaceuticals in a research note on Tuesday, November 5th. Needham & Company LLC boosted their price objective on shares of BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the company a “buy” rating in a research note on Monday. Finally, Barclays increased their target price on BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the stock an “equal weight” rating in a research report on Tuesday, November 5th. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $15.17.

BioCryst Pharmaceuticals Stock Down 2.4 %

The company has a market cap of $1.46 billion, a P/E ratio of -11.57 and a beta of 1.76. The company has a 50 day moving average price of $7.59 and a 200-day moving average price of $7.61.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its quarterly earnings results on Monday, November 4th. The biotechnology company reported ($0.07) EPS for the quarter, hitting analysts’ consensus estimates of ($0.07). The company had revenue of $117.10 million for the quarter, compared to the consensus estimate of $113.99 million. The firm’s quarterly revenue was up 35.1% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.19) earnings per share. On average, research analysts expect that BioCryst Pharmaceuticals, Inc. will post -0.38 earnings per share for the current fiscal year.

Institutional Investors Weigh In On BioCryst Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of BCRX. Deerfield Management Company L.P. Series C boosted its position in shares of BioCryst Pharmaceuticals by 62.9% during the 2nd quarter. Deerfield Management Company L.P. Series C now owns 8,135,804 shares of the biotechnology company’s stock valued at $50,279,000 after purchasing an additional 3,140,804 shares in the last quarter. Cubist Systematic Strategies LLC lifted its stake in BioCryst Pharmaceuticals by 528.0% during the second quarter. Cubist Systematic Strategies LLC now owns 1,112,232 shares of the biotechnology company’s stock valued at $6,874,000 after purchasing an additional 935,132 shares during the last quarter. Fisher Asset Management LLC boosted its holdings in BioCryst Pharmaceuticals by 16.9% during the third quarter. Fisher Asset Management LLC now owns 3,338,062 shares of the biotechnology company’s stock worth $25,369,000 after buying an additional 481,359 shares in the last quarter. BNP Paribas Financial Markets grew its position in BioCryst Pharmaceuticals by 472.0% in the third quarter. BNP Paribas Financial Markets now owns 496,784 shares of the biotechnology company’s stock worth $3,776,000 after buying an additional 409,938 shares during the last quarter. Finally, Principal Financial Group Inc. increased its holdings in shares of BioCryst Pharmaceuticals by 1,058.1% in the third quarter. Principal Financial Group Inc. now owns 411,414 shares of the biotechnology company’s stock valued at $3,127,000 after buying an additional 375,890 shares in the last quarter. 85.88% of the stock is currently owned by institutional investors.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.